Skip to main content
Figure 2 | World Journal of Surgical Oncology

Figure 2

From: Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer

Figure 2

ORR of Endostar combined with PBDC versus PBDC alone for treating NSCLC. GP, gemcitabine + cisplatin; NP, vinorelbine + cisplatin; OR, odds ratio; ORR, overall response rate; PBDC, platinum-based doublet chemotherapy; PP, paclitaxel + cisplatin; RT, radiotherapy; TC, paclitaxel + carboplatin; TP, docetaxel + cisplatin.

Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us